Literature DB >> 19933626

Bidimensional measurements in brain tumors: assessment of interobserver variability.

James M Provenzale1, Claro Ison, David Delong.   

Abstract

OBJECTIVE: Bidimensional tumor measurements indicating a greater than 25% increase in tumor size are generally accepted as indicating tumor progression. We hypothesized that use of digital images and a homogeneous reader population would have lower interobserver variability than in previous studies. SUBJECTS AND METHODS: Eight board-certified radiologists measured tumor diameters in three planes in two consecutive MRI examinations of 22 patients with contrast-enhancing high-grade brain tumors. Products of tumor measurements were calculated, and determinations were made about tumor progression (> 25% increase in area). A variance components model was run on diameter products and the ratios of consecutive maximal diameter products. The variance components included patient examination effect, reader effect, and residual effect.
RESULTS: Complete agreement was found among readers in 10 cases (45%), all indicating stable disease. In the other 12 cases, at least one reader considered progressive disease present. The variance components model showed variance due to readers was small, indicating only modest bias among readers. The residual variance component was large (0.038), indicating that repeated measurements on the same image likely are variable even for the same reader. This variability in measurement implies that repeated measurements by the typical reader have an inherent 14% false-positive rate in the diagnosis of progression of tumors that are stable.
CONCLUSION: Our hypothesis was disproved. We found substantial interreader disagreement and indications that the very nature of the measurement method produces a high rate of false-positive readings of stable tumors. These findings should be considered in interpretation of images with this widely accepted criterion for brain tumor progression.

Entities:  

Mesh:

Year:  2009        PMID: 19933626     DOI: 10.2214/AJR.09.2615

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  27 in total

1.  Assessment of intra-observer variability in measurement of high-grade brain tumors.

Authors:  James M Provenzale; Michael C Mancini
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Proton MR spectroscopy of brain abscesses.

Authors:  E Kapsalaki; K N Fountas
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-25       Impact factor: 3.825

Review 3.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

4.  Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state.

Authors:  Tyler C Steed; Jeffrey M Treiber; Birra Taha; H Billur Engin; Hannah Carter; Kunal S Patel; Anders M Dale; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2020-06-15       Impact factor: 4.130

5.  Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.

Authors:  Raymond Y Huang; Robert J Young; Benjamin M Ellingson; Harini Veeraraghavan; Wei Wang; Florent Tixier; Hyemin Um; Rasheed Nawaz; Tracy Luks; John Kim; Elizabeth R Gerstner; David Schiff; Katherine B Peters; Ingo K Mellinghoff; Susan M Chang; Timothy F Cloughesy; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

6.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Authors:  Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

7.  Response assessment in high-grade glioma: tumor volume as endpoint.

Authors:  Raymond Huang
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

Review 8.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

9.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 10.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.